<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">The risk of retinopathy associated with hydroxychloroquine treatment has been well documented for decades. It was recently shown that the prevalence of retinopathy ranged from 5.2 to 7.5% in patients who were treated for &gt;5Â years [
 <xref rid="bb0155" ref-type="bibr">31</xref>]. There is no need to use HCQ for such extended periods for as a post-exposure medication for COVID-19.
</p>
